secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2026-10-09T18:00:32+00:00
Accession:  0001731122-26-001333
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Lunai Bioworks asks Nasdaq to suspend LNAI trading amid Seven Points Capital litigation
--------------------------------------------------------------------------------

- On October 9, 2026, Lunai Bioworks submitted a formal request to Nasdaq to immediately suspend trading of its common stock, ticker LNAI.
- The request cites court-ordered discovery records in Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC, D. Del.
- Submission describes substantial short selling, locate deficiencies, concentrated failures to deliver, and questions whether LNAI trading is fair and orderly.
- Lunai says Nasdaq has not yet decided; the request alone does not halt trading, and Nasdaq retains authority to suspend trading.
- Second Amended Complaint was filed August 26, 2026; litigation remains pending and allegations are not yet adjudicated, per the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226001333/0001731122-26-001333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226001333/e8001_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-001333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer